An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)

Trial Profile

An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Lonafarnib (Primary) ; Ritonavir
  • Indications Hepatitis D
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms LOWR HDV-1; LOWR-1
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 21 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, results of pooled analysis from LOWR HDV-1 and LOWR HDV-2 studies have been presented at The International Liver Congress 2017.
    • 17 Apr 2016 Results hepatitis deltavirus kinetics data were presented at The International Liver Congress 2016.
    • 25 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top